Clinical Trial Update: 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the radiopharmaceutical 177Lu-PP-F11N for receptor-targeted therapy and imaging in metastatic medullary thyroid carcinoma and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Medullary Thyroid Carcinoma
• Pulmonary Neuroendocrine Tumor
• Thymic Neuroendocrine Tumor

Drugs mentioned

• 177Lu-PP-F11N (Lutetium-177-PP-F11N)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Thyroid Cancer, Medullary, Neuroendocrine Tumor of the Lung Grade 1 and 2 | Phase 1 | Status: ACTIVE_NOT_RECRUITING